The Overlap Between Bronchiectasis and COPD: Implications for Drug Development
- Understand the epidemiology and implications of bronchiectasis-COPD overlap
- Explore how the evolving clinical development landscape, including the approval of the first disease modifying therapy for non‑CF bronchiectasis, reshapes expectations for trial design, endpoints, and patient selection, and challenges traditional views of COPD as a single therapeutic entity
- Learn how patients with bronchiectasis-COPD overlap may respond differently to standard COPD therapies due to neutrophilic inflammation, chronic infection, and structural lung disease, highlighting key challenges and opportunities for developing targeted treatments in COPD